Table 2.
Frequency of risk classes and SUVmax grade groups in No Vac- and Vac-group.
| Lymphadenopathy Characteristics | No Vac-Group (n = 375) | All Vac Group (n = 437) | p |
|---|---|---|---|
| HLN | 55 (15%) | 120 (27%) | <0.001 |
| MHL | 28 (23%) | ||
| VAHL | 65 (54%) | ||
| EqHL | 27 (23%) | ||
| Median SUVmax | 5.3 (1.5–33.4) | 4.1 (1.4–24.5) | p = 0.141 |
| Grading uptake | |||
| Grade 1 | 6 (11%) | 13 (11%) | |
| Grade 2 | 7 (13%) | 45 (37%) | |
| Grade 3 | 42 (76%) | 62 (52%) |
MHL: malignant hypermetabolic lymphadenopathy; VAHL: vaccine-associated hypermetabolic lymphadenopathy; EqHL: equivocal hypermetabolic lymphadenopathy; SUVmax: maximum standardized uptake value.